Fondation Recherches 3R - Page d'accueil
Projets


 

de | fr | en   Imprimer

Liste des projets

3R and Training

ANIMAL HEALTH

88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 

ANIMAL WELFARE

122-10Improved perioperative analgesia and reduced stress during recovery for the experimental animal: ultrasound-guided sciatic and femoral nerve block in sheep and quantitative assessment of block quality
Rohrbach H., Dr, Institute for Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Switzerland
 
88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 

PAIN

88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 

DISTRESS

88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 

3R EDUCATION

88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 
49-96Cours de formation continue universitaire intitulé “l’utilisation de l’animal en pharmaco/toxicologie et ses alternatives”
Wagnières S., Dr. ès sciences, Service de formation continue, BEB, University of Lausanne, Switzerland
 

OECD-GUIDELINE

123-10Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
114-08Reduction of the number of animals used in the Fish Acute Toxicity Test
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 

REDUCTION

144-15Development of in vitro three-dimensional multi-cellular culture models to study the role of heterotypic interactions during colorectal carcinomatous invasive process
Rüegg, C., Prof. Dr., Department of OMI, University of Fribourg, Switzerland
 
143-15An advanced in-vitro model of pulmonary inflammation based on a novel lung-on-chip technology
Guenat, O., Prof. Dr., ARTORG Center, University of Bern & Pneumology and Thoracic Surgery Clinics, University Hospital of Bern, Switzerland
 
134-12Cardiovascular simulator with autoregulation
Vandenberghe S,, Prof., ARTORG Center for Biomedical Research, University of Bern, Switzerland
 
133-12Development of an in vitro system to grow and investigate vascular endothelial cells under physiological flow conditions
Rieben R., Prof., Department of Clinical Research, University of Bern, Switzerland
 
132-12Identification of predictive in vitro markers of hematopoietic stem cell function
Lutolf M. P., Prof., Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
 
131-12Antibody-phage-selection strategy for application in non-specialized laboratories
Heinis Ch., Prof., Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
 
130-11Establishment of an in-vitro organ-slice defect model for meniscal repair in orthopaedic research
Hunziker E., Prof., Center of Regenerative Medicine for Skeletal Tissues, University of Bern, Switzerland
 
129-11The use of microfluidic chambers to study axonal transport in PTEN and SOCS3 dependent axonal regeneration
He Zhigang, Prof., Children's Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115
 
128-11Genetic modification of the human airway epithelium – a paradigmatic system to study host responses to human respiratory viruses
Thiel V., PD Dr., Institut für Immunbiologie, Kantonsspital St. Gallen, Switzerland
 
127-11Establishing a novel system for quantitative production of murine basophils in vitro
Kaufmann T., PD Dr., Institute of Pharmacology, University of Bern, Switzerland
 
126-11Development and validation of a model to investigate myeloid-cell homeostasis
Benarafa C., Dr., Theodor Kocher Institute, University of Bern, Switzerland
 
123-10Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
121-10Organotypic spinal cord slices to study SCI and MS like lesions
Chrast R., Prof. Dr., Department of Medical Genetics, University of Lausanne, Switzerland
 
118-10Engineering of an in vitro hepatocyte tissue system for malaria liver infection research
Mancama D., Dr., Systems Biology, Biosciences Unit, CSIR, South Africa
 
116-09Organotypic brain-slice cultures derived from regularly-slaughtered animals as an in-vitro alternative for the investigation of neuroinfectious diseases in ruminants
Oevermann A., Dr., Vetsuisse Faculty, University of Berne, Switzerland
 
115-09Engineering of a human brain tumour model to replace animal experimentation
Preynat-Seauve O., Dr., University of Geneva, Switzerland
 
114-08Reduction of the number of animals used in the Fish Acute Toxicity Test
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
113-08Generic in-vitro evaluation assay for immunological correlates of protection to replace animal challenge infections
Summerfield A., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
112-08A novel in-vitro model for the holistic assessment and optimisation of engineered tissue for functional cartilage repair
Luo Z., Dr., Leeds Dental Institute, Leeds LS9 9LU, UK
 
111-08Establishment of an organ ex-vivo tissue slice model for cardiovascular research in particular for therapeutic atherosclerosis targeting
Hunziker P., PD Dr., Intensive Care Unit, University Hospital Basel, Switzerland
 
105-06Establishment of an in vitro system for the prediction of the degree of virulence of classical swine fever virus isolates
Ruggli N., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
104-06Development of in vitro strategies to propagate and characterize hemotrophic mycoplasmas
Hofmann-Lehmann R., Prof. Dr., Clinical Laboratory, Vetsuisse-Faculty, University of Zurich, Switzerland
 
103-06An in vitro Model of Central Nervous System Infection and Regeneration: Neuronal Stem Cells as Targets of Brain Damage & Regenerative Therapies in Bacterial Meningitis.
Leib S.L., Prof. Dr., Institute of Infectious Diseases, University of Bern, Switzerland
 
102-06Isolated, autologous blood-perfused heart: Replacement of heterotopic heart transplantation
Bogdanova A, Dr., Institute of Veterinary Physiology, University of Zurich, Switzerland
 
101-06Organotypic CNS slice cultures as an in-vitro model for immune mediated tissue damage and repair in multiple sclerosis
Goebels N., Prof. Dr., Heinrich-Heine University Düsseldorf Medical Faculty, Department of Neurology
 
100-06Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish
Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
99-05The NEMO network (Non-mammalian Experimental Models for the study of bacterial infections)
Cosson P., Prof. Dr., Département de Physiologie Cellulaire et Métabolisme, Centre Medical Universitaire Genève, Geneva 4, Switzerland
 
98-05Establishment of a murine syngeneic co-culture system of intestinal epithelial cells with intraepithelial T lymphocyte subsets.
Mueller Ch., Prof. Dr., Institute of Pathology, University of Bern, Switzerland
 
97-05Development of a three-dimensional enteric cell culture model for in vitro studies of the intestinal eukaryotic parasites Cryptosporidium spp.
Mathis A., Prof. Dr., Institute of Parasitology, University of Zürich, Switzerland
 
95-05Development of QSAR-Models for Classification and Prediction of Baseline Toxicity and of Uncoupling of Energy Transduction
Spycher S. + Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
94-04Tumor targeted reporter gene expression to improve and refine traditional models of Tumor growth and metastasis
Vorburger S., Dr., Department of Clinical Research, Visceral and Transplantation Surgery, University Hospital Bern, Switzerland
 
93-04Development of a novel multicellular 3-dimensional blood brain barrier in vitro model
Ogunshola O., Dr., Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zürich, Switzerland
 
92-04Adjuvanticity of microbial-derived particles and synthetic analogs in vitro.
Padovan E., Prof. Dr., Instituto Gulbenkian de Ciência, Oerias, Portugal
 
91-04Establishment and validation of a Choroid Plexus Model to study drug transport
Fricker G., Prof. Dr., Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls Universität Heidelberg, Germany
 
90-03A non-mammalian system to study bacterial infections
Cosson P., Prof. Dr., Centre Medical Universitaire, Dpt de Morphologie, Geneva 4, Switzerland
 
89-03In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction
Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland
 
87-03Information on serum free cell lines, an interactive database
Strebel C., dipl. Ing. FH, CePower GmbH, Wädenswil, Switzerland
 
86-03Bone Formation in a loading chamber for ex-vivo bone culture
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
84-02Direct cloning of human antibodies from purified specific B-cells
Wirthmueller U., Dr., Institute of Immunology, University Hospital Bern, Switzerland
 
83-02The development of an in vitro intervertebral disc organ culture system
Lee C., Dr., Biochemistry and Cell Biology Unit; AO Research Institute, Davos, Switzerland
 
82-02Magnetic Resonance Imaging (MRI) for the non-invasive assessment of lung inflammation and pulmonary function in the rat
Beckmann N., PD Dr., Novartis Pharma AG Basel Novartis Institute of Biomedical Research (NIBR), Basel, Switzerland
 
81-02In vitro model for the testing of endothelial cell activation and damage in whole blood
Rieben R., Prof. Dr., Heart Transplantation Laboratory, Cardiology, University Hospital Bern, Switzerland
 
80-01Induction of a primary T cell mediated immune response against drugs and drug metabolites in vitro
Pichler, W.J., Prof. Dr., Division Allergology, University Hospital Bern, Switzerland
 
79-01Screening methods for repellents and attachment deterrents for ticks in-vitro
Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland
 
78-01Validation of a combined perfusion/loading chamber for ex-vivo bone metabolic studies and bone-biomaterial interactions
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
77-01Reproducibility and external validity of findings from animal experiments: influence of housing conditions
Würbel H., Prof. Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 
76-01Development of a model of heart angiogenesis in vitro
Battegay E., Prof. Dr., Outpatient Department of Internal Medicine and Department of Research, University Hospital Basel, Switzerland
 
75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 
74-00Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test
Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
73-00Generation and functional characterization of a clonal murine periportal Kupffer cell line from H-2Kb -tsA58 mice
Landmann R., Prof. Dr., Division of Infectious Diseases, Department of Research, University Hospital Basel, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
70-99Sensory irritant screening using a stable cell line expressing the vanilloid receptor
Baumann T., Prof. Dr., Dept. of Neurological Suregry,Oregon Health and Sciences University, Portland, USA
 
69-99A human neural cell line as in vitro model system for the excitotoxic cascade during stroke
Bicker G., Prof. Dr., Abt. Zellbiologie, Physiologisches Institut, Stiftung Tierärztliche Hochschule Hannover, Germany
 
68-99Genetic analysis of a 3D in vitro model of the rheumatic pannus tissue
Illges H., PD Dr., Biotechnologie Institut Thurgau an der Universität Konstanz, Switzerland
 
67-99Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals
Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland
 
66-99The influence of enriched housing conditions on experimental results in laboratory mice
Baumans V., Prof. Dr., Department of Laboratory Animal Science, University of Utrecht, Netherland
 
65-98Reconstructed human epidermis as model for predicting irritancy
Ponec M., Prof. Dr., Skin Research Laboratory, Department of Dermatology, Leiden University Medical Center, Netherland
 
63-97In vitro study of pathogenesis of sepsis in a conditionally immortalized Kupffer cell line
Landmann R., Prof. Dr., Division Infectious Deseases, Department Research, University Hospital Basel, Switzerland
 
62-97Development of an in vitro model system for cartilage invasion by synovial fibroblasts
Gay R. E., Prof. Dr., Department of Rheumatology, University Hospital Zürich, Switzerland
 
61-97An in vitro model to study mechanical forces on human venous coronary bypass graft stenosis: Molecular targeting by pharmacological intervention
Lüscher T. F., Prof. Dr., Cardiovascular Research, Institute of Physiology, University Zürich and Cardiology, University Hospital Zürich, Switzerland
 
55-96Computer-aided identification of ochratoxin antagonists
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland
 
54-96Elaboration of an in vitro screening method for testing the effect of drugs and other compounds on the renal transport of uric acid
Roch-Ramel F., Prof. Dr., Institute of Pharmacoly and Toxicology, University of Lausanne, Switzerland
 
53-96Axenic cultivation of amastigote forms of Leishmania
Grimm F., Dr. phil. nat., Institute of Parasitology, University of Zürich, Switzerland
 
50-96Morphometric Analysis of human articular cartilage
Hunziker E., Prof. Dr., M.E.Müller Institut für Biomechanik, University of Bern, Switzerland
 
48-96Utilization of a model of culture of human intestinal cell lines for the study of the pathogenicity of different strains of Clostridium difficile
Kraehenbuhl J.-P., Prof. Dr., Institut Suisse de Recherches Expérimentales sur le Cancer (ISREC), Switzerland
 
47-96Development of an in vitro system for the detection of estrogenic compounds (xenoestrogens)
Fent K., PD Dr., Swiss Federal Institute for Environmental Science and Technology (EAWAG), Switzerland
 
46-96Development and Validation of an In Vitro Model Simulating Mechanical Ventilation-Induced Inflammation
Pugin J., Dr., Division des Soins Intensifs de Médecine, Hôpital Cantonal Universitaire, Genève, Suisse
 
45-96Replacement of mouse and rat antibody production test by polymerase chain reaction assays
Homberger F., Prof. Dr., Department of Microbiology and Immunology, Weill Medical College of Cornell University and the Memorial Sloaan-Kettering Center, USA
 
43-95Short term assay for liver cell activated neurotoxic drugs
Maier P., Prof. Dr., Institute of Toxicology, Swiss Federal Institute of Technology (ETH) and University of Zürich, Switzerland
 

REFINEMENT

134-12Cardiovascular simulator with autoregulation
Vandenberghe S,, Prof., ARTORG Center for Biomedical Research, University of Bern, Switzerland
 
127-11Establishing a novel system for quantitative production of murine basophils in vitro
Kaufmann T., PD Dr., Institute of Pharmacology, University of Bern, Switzerland
 
123-10Use of "moribund" stage in the acute fish toxicity test according to OECD guideline 203 and its effect on LC50 values
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
122-10Improved perioperative analgesia and reduced stress during recovery for the experimental animal: ultrasound-guided sciatic and femoral nerve block in sheep and quantitative assessment of block quality
Rohrbach H., Dr, Institute for Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Switzerland
 
120-10Development of non-invasive strategies to study corticospinal neuron disease, injury and repair
Jabaudon D., Prof. Dr., Dpt. of Basic Neurosciences, University of Geneva, Switzerland
 
119-10Non invasive electrical monitoring of the population spiking activity in the central nervous system
Gonzalez Andino S.L., Dr., University of Geneva and Geneva University Hospital, Switzerland
 
114-08Reduction of the number of animals used in the Fish Acute Toxicity Test
Rufli H., Dr., ecotoxsolution, Basel, Switzerland
 
96-05Assessment of pain and stress in mice by monitoring gene expression changes
Cinelli P., Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 
94-04Tumor targeted reporter gene expression to improve and refine traditional models of Tumor growth and metastasis
Vorburger S., Dr., Department of Clinical Research, Visceral and Transplantation Surgery, University Hospital Bern, Switzerland
 
88-03Assessing animal health and welfare and recognising pain and distress
Flecknell P., Prof. Dr., Comparative Biology Centre, University of Newcastle, UK
 
87-03Information on serum free cell lines, an interactive database
Strebel C., dipl. Ing. FH, CePower GmbH, Wädenswil, Switzerland
 
82-02Magnetic Resonance Imaging (MRI) for the non-invasive assessment of lung inflammation and pulmonary function in the rat
Beckmann N., PD Dr., Novartis Pharma AG Basel Novartis Institute of Biomedical Research (NIBR), Basel, Switzerland
 
77-01Reproducibility and external validity of findings from animal experiments: influence of housing conditions
Würbel H., Prof. Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 
71-00Detection and characterisation of signs of pain in mice by the combined use of a telemetry model and behavioural observations
Arras M., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
66-99The influence of enriched housing conditions on experimental results in laboratory mice
Baumans V., Prof. Dr., Department of Laboratory Animal Science, University of Utrecht, Netherland
 
64-97Use of three-dimensional brain cell cultures as a model for ischemia-related research
Honegger P., Prof. Dr., Institute of Physiology, Faculty of Medicine, University of Lausanne, Switzerland
 
59-97Phenotype characterisation and health monitoring of transgenic mice
Mertens C., dipl. phil. nat., Zürcher Tierschutz (SPCA), Zürich, Switzerland
 
51-96Establishment of endotoxin limits in porcine vaccines: animal welfare aspects
Cussler K., Dr., Paul Ehrlich Institut, Langen, Germany
 
45-96Replacement of mouse and rat antibody production test by polymerase chain reaction assays
Homberger F., Prof. Dr., Department of Microbiology and Immunology, Weill Medical College of Cornell University and the Memorial Sloaan-Kettering Center, USA
 

REPLACEMENT

146-15Validation of a novel cell-based approach to study thyroidal physiology: Reduction and/or replacement of experiments with rodents
Sykiotis, G., PhD, Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Lausanne, Switzerland
 
145-15Combining computational modelling with in-vitro cellular responses in order to predict chemical impact on fish growth
Schirmer, K., Prof. Dr., EAWAG, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, Switzerland
 
143-15An advanced in-vitro model of pulmonary inflammation based on a novel lung-on-chip technology
Guenat, O., Prof. Dr., ARTORG Center, University of Bern & Pneumology and Thoracic Surgery Clinics, University Hospital of Bern, Switzerland
 
142-14Validation of human stem-cell pluripotency using a bioreactor-based culturing system instead of a murine model to effect the development of embryoid bodies into teratomas
De Geyter, C., Prof. Dr., Department of Biomedicine, Department of Biomedicine, University Hospital, University of Basel, Switzerland
 
133-12Development of an in vitro system to grow and investigate vascular endothelial cells under physiological flow conditions
Rieben R., Prof., Department of Clinical Research, University of Bern, Switzerland
 
132-12Identification of predictive in vitro markers of hematopoietic stem cell function
Lutolf M. P., Prof., Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
 
131-12Antibody-phage-selection strategy for application in non-specialized laboratories
Heinis Ch., Prof., Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland
 
130-11Establishment of an in-vitro organ-slice defect model for meniscal repair in orthopaedic research
Hunziker E., Prof., Center of Regenerative Medicine for Skeletal Tissues, University of Bern, Switzerland
 
129-11The use of microfluidic chambers to study axonal transport in PTEN and SOCS3 dependent axonal regeneration
He Zhigang, Prof., Children's Hospital and Department of Neurology, Harvard Medical School, Boston, MA 02115
 
128-11Genetic modification of the human airway epithelium – a paradigmatic system to study host responses to human respiratory viruses
Thiel V., PD Dr., Institut für Immunbiologie, Kantonsspital St. Gallen, Switzerland
 
125-11Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins
Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland;
 
124-10Comparative in vitro and in vivo testing on biofilm formation on the surface of bone grafts
Clauss M., Dr., Kantonsspital Liestal, Orthopädie, Liestal, Switzerland
 
121-10Organotypic spinal cord slices to study SCI and MS like lesions
Chrast R., Prof. Dr., Department of Medical Genetics, University of Lausanne, Switzerland
 
119-10Non invasive electrical monitoring of the population spiking activity in the central nervous system
Gonzalez Andino S.L., Dr., University of Geneva and Geneva University Hospital, Switzerland
 
118-10Engineering of an in vitro hepatocyte tissue system for malaria liver infection research
Mancama D., Dr., Systems Biology, Biosciences Unit, CSIR, South Africa
 
116-09Organotypic brain-slice cultures derived from regularly-slaughtered animals as an in-vitro alternative for the investigation of neuroinfectious diseases in ruminants
Oevermann A., Dr., Vetsuisse Faculty, University of Berne, Switzerland
 
115-09Engineering of a human brain tumour model to replace animal experimentation
Preynat-Seauve O., Dr., University of Geneva, Switzerland
 
113-08Generic in-vitro evaluation assay for immunological correlates of protection to replace animal challenge infections
Summerfield A., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
112-08A novel in-vitro model for the holistic assessment and optimisation of engineered tissue for functional cartilage repair
Luo Z., Dr., Leeds Dental Institute, Leeds LS9 9LU, UK
 
111-08Establishment of an organ ex-vivo tissue slice model for cardiovascular research in particular for therapeutic atherosclerosis targeting
Hunziker P., PD Dr., Intensive Care Unit, University Hospital Basel, Switzerland
 
110-08Development of an in-vitro assay for the screening of antischistosomal drugs
Keiser J., Prof. Dr., Swiss Tropical Institute, University of Basel,Switzerland
 
109-08Evaluation of lipid fractions for the substitution of serum in cell culture media
Honegger P., Prof. Dr., Département de Physiologie, Université de Lausanne, Switzerland
 
108-07Cultured piscine hepatocytes as an in-vitro source of metabolic clearance data that is currently gleaned by in-vivo bioaccumulation testing in fish
Segner H., Prof. Dr., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Berne, Switzerland
 
107-07Evaluation of an in vitro model to identify host parameters associated with virulence of Toxoplasma gondii strains
D’Souza S., Dr., Pasteur Institute of Brussels-ISP,1180-Uccle, Belgium
 
106-07Standardization and Pre-validation of MucilAir: A novel in vitro cell model of the human airway epithelium for testing acute and chronic effects of chemical compounds
Huang S., Dr., Epithelix Sàrl, Plan-les-Ouates, Geneva, Switzerland
 
105-06Establishment of an in vitro system for the prediction of the degree of virulence of classical swine fever virus isolates
Ruggli N., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
104-06Development of in vitro strategies to propagate and characterize hemotrophic mycoplasmas
Hofmann-Lehmann R., Prof. Dr., Clinical Laboratory, Vetsuisse-Faculty, University of Zurich, Switzerland
 
103-06An in vitro Model of Central Nervous System Infection and Regeneration: Neuronal Stem Cells as Targets of Brain Damage & Regenerative Therapies in Bacterial Meningitis.
Leib S.L., Prof. Dr., Institute of Infectious Diseases, University of Bern, Switzerland
 
102-06Isolated, autologous blood-perfused heart: Replacement of heterotopic heart transplantation
Bogdanova A, Dr., Institute of Veterinary Physiology, University of Zurich, Switzerland
 
101-06Organotypic CNS slice cultures as an in-vitro model for immune mediated tissue damage and repair in multiple sclerosis
Goebels N., Prof. Dr., Heinrich-Heine University Düsseldorf Medical Faculty, Department of Neurology
 
100-06Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish
Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
99-05The NEMO network (Non-mammalian Experimental Models for the study of bacterial infections)
Cosson P., Prof. Dr., Département de Physiologie Cellulaire et Métabolisme, Centre Medical Universitaire Genève, Geneva 4, Switzerland
 
98-05Establishment of a murine syngeneic co-culture system of intestinal epithelial cells with intraepithelial T lymphocyte subsets.
Mueller Ch., Prof. Dr., Institute of Pathology, University of Bern, Switzerland
 
97-05Development of a three-dimensional enteric cell culture model for in vitro studies of the intestinal eukaryotic parasites Cryptosporidium spp.
Mathis A., Prof. Dr., Institute of Parasitology, University of Zürich, Switzerland
 
95-05Development of QSAR-Models for Classification and Prediction of Baseline Toxicity and of Uncoupling of Energy Transduction
Spycher S. + Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
93-04Development of a novel multicellular 3-dimensional blood brain barrier in vitro model
Ogunshola O., Dr., Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zürich, Switzerland
 
92-04Adjuvanticity of microbial-derived particles and synthetic analogs in vitro.
Padovan E., Prof. Dr., Instituto Gulbenkian de Ciência, Oerias, Portugal
 
91-04Establishment and validation of a Choroid Plexus Model to study drug transport
Fricker G., Prof. Dr., Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls Universität Heidelberg, Germany
 
90-03A non-mammalian system to study bacterial infections
Cosson P., Prof. Dr., Centre Medical Universitaire, Dpt de Morphologie, Geneva 4, Switzerland
 
89-03In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction
Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland
 
87-03Information on serum free cell lines, an interactive database
Strebel C., dipl. Ing. FH, CePower GmbH, Wädenswil, Switzerland
 
86-03Bone Formation in a loading chamber for ex-vivo bone culture
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
84-02Direct cloning of human antibodies from purified specific B-cells
Wirthmueller U., Dr., Institute of Immunology, University Hospital Bern, Switzerland
 
83-02The development of an in vitro intervertebral disc organ culture system
Lee C., Dr., Biochemistry and Cell Biology Unit; AO Research Institute, Davos, Switzerland
 
81-02In vitro model for the testing of endothelial cell activation and damage in whole blood
Rieben R., Prof. Dr., Heart Transplantation Laboratory, Cardiology, University Hospital Bern, Switzerland
 
80-01Induction of a primary T cell mediated immune response against drugs and drug metabolites in vitro
Pichler, W.J., Prof. Dr., Division Allergology, University Hospital Bern, Switzerland
 
79-01Screening methods for repellents and attachment deterrents for ticks in-vitro
Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland
 
78-01Validation of a combined perfusion/loading chamber for ex-vivo bone metabolic studies and bone-biomaterial interactions
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
76-01Development of a model of heart angiogenesis in vitro
Battegay E., Prof. Dr., Outpatient Department of Internal Medicine and Department of Research, University Hospital Basel, Switzerland
 
75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 
74-00Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test
Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
70-99Sensory irritant screening using a stable cell line expressing the vanilloid receptor
Baumann T., Prof. Dr., Dept. of Neurological Suregry,Oregon Health and Sciences University, Portland, USA
 
69-99A human neural cell line as in vitro model system for the excitotoxic cascade during stroke
Bicker G., Prof. Dr., Abt. Zellbiologie, Physiologisches Institut, Stiftung Tierärztliche Hochschule Hannover, Germany
 
68-99Genetic analysis of a 3D in vitro model of the rheumatic pannus tissue
Illges H., PD Dr., Biotechnologie Institut Thurgau an der Universität Konstanz, Switzerland
 
67-99Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals
Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland
 
65-98Reconstructed human epidermis as model for predicting irritancy
Ponec M., Prof. Dr., Skin Research Laboratory, Department of Dermatology, Leiden University Medical Center, Netherland
 
60-97Transgenic protozoa (Trypanosoma spp.) as an alternative to transgenic animals
Roditi I., Prof. Dr., Institutes of General Microbiology and Parasitology, University of Bern, Switzerland
 
52-96Development of an interleukin-1 (IL-1) assay with rabbit blood as an alternative to the rabbit pyrogen test
Hartung T., Prof.. Dr., Biochemical Pharmacology, University of Konstanz, Germany
 
43-95Short term assay for liver cell activated neurotoxic drugs
Maier P., Prof. Dr., Institute of Toxicology, Swiss Federal Institute of Technology (ETH) and University of Zürich, Switzerland
 


TOP